Miracle Mile Advisors’s Novartis NVS Stock Holding History

Miracle Mile Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$625K	Buy	4,089 +438	+12%	+$67.1K	0.01%	528
2025 Q4	$503K	Buy	3,651 +32	+0.9%	+$4.19K	0.01%	562
2025 Q3	$464K	Buy	3,619 +328	+10%	+$40K	0.01%	568
2025 Q2	$398K	Buy	+3,291	New	+$371K	0.01%	535

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Miracle Mile Advisors's NVS Position: Q1 2026 in Review

Miracle Mile Advisors increased its Novartis (NVS) stake by 12% in Q1 2026, buying an estimated $67.1K and bringing the position to 4,089 shares worth $625K. The position accounts for 0.01% of the portfolio, ranked #528.

Miracle Mile Advisors first reported a position in NVS in Q2 2025 and has held it in 4 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Miracle Mile Advisors held 4,089 shares of Novartis worth $625K as of Q1 2026.
Miracle Mile Advisors bought 438 Novartis shares in Q1 2026, an estimated $67.1K.
Novartis made up 0.01% of Miracle Mile Advisors's portfolio in Q1 2026, its #528 holding.
Miracle Mile Advisors first reported a position in Novartis in Q2 2025 and has held it in 4 quarters since.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Miracle Mile Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.